PaxMedica | Investor Presentation Deck | 24 slides — playbook

PaxMedica | Investor Presentation Deck | 24 slides

PaxMedica · 2022-10

arc beats above · slides in the middle · loops below · scroll → 1 LOOPS

Deck intelligence map

5

coverage by narrative range · generated from this deck JSON

Narrative range 8 total

Metadata

Components

Metrics

Tools

Frameworks

Beats

Loops

Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits

— 0/1 slides

100% 1/1 slides · 2 hits

— 0/1 slides

100% 1/1 slides · 2 hits 100% 1/1 slides Solution 2 slides 100% 2/2 slides 100% 2/2 slides · 8 hits

— 0/2 slides

100% 2/2 slides

— 0/2 slides

100% 2/2 slides · 4 hits 50% 1/2 slides Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits

— 0/1 slides

100% 1/1 slides · 2 hits

— 0/1 slides

100% 1/1 slides · 2 hits 100% 1/1 slides Product 2 slides 100% 2/2 slides 100% 2/2 slides · 8 hits

— 0/2 slides

100% 2/2 slides

— 0/2 slides

100% 2/2 slides · 4 hits 50% 1/2 slides Team 2 slides 100% 2/2 slides 100% 2/2 slides · 15 hits

— 0/2 slides

— 0/2 slides

— 0/2 slides

100% 2/2 slides

— 0/2 slides

Slide inventory

24

every slide · same image gating as the playbook

01

front_matter

Open slide detail

02

other

Open slide detail

03

summarize

Open slide detail

04

summarize

Open slide detail

05

The slide uses a standard team bio layout with headshots and titles, followed by a logo grid to establish credibility.other

Open slide detailBeat · Team

06

The slide lists board members followed by a grid of company logos representing their professional backgrounds.other

Open slide detailBeat · Team

07

transition

Open slide detail

08

Focuses on regulatory strategy and potential financial upside from FDA Priority Review Vouchers.other

Open slide detail

09

Focuses on the regulatory milestone of an NDA filing and the associated Priority Review Voucher (PRV) opportunity.plan_implementation

Open slide detail

10

The slide outlines three key workstreams: Regulatory (FDA guidance), Clinical (registrational study), and CMC Supply Chain.plan_implementation

Open slide detail

11

The slide highlights the strategic importance of the first US approval for Suramin.plan_implementation

Open slide detail

12

transition

Open slide detail

13

The slide uses a background map of the world to emphasize the global nature of the condition, despite the specific US prevalence statistic.size_opportunity

Open slide detailBeat · ProblemLoop · Cost Of Inaction

14

The slide uses a biological process diagram to explain the drug's mechanism.present_solution

Open slide detailBeat · SolutionLoop · Cost Of Inaction

15

Includes a medical illustration of the intranasal drug delivery pathway to the brain.present_solution

Open slide detailBeat · Solution

16

The slide uses a medical/scientific aesthetic with a brain illustration and a healthcare professional.front_matter

Open slide detail

17

The slide outlines a randomized, double-blind, placebo-controlled, dose-ranging proof of concept study.present_framework

Open slide detail

18

analyze_data

Open slide detail

19

The chart highlights the 'ABC Core' as the primary endpoint.analyze_data

Open slide detail

20

The slide displays two line charts comparing PAX-101 against placebo across multiple time points, with error bars indicating standard error.show_traction

Open slide detail

21

Data represents change from baseline to week 14 for ITT population.analyze_data

Open slide detail

22

The slide uses a human-centric image to emphasize the clinical impact of the drug.show_traction

Open slide detail

23

plan_implementation

Open slide detail

24

state_next_steps

Open slide detail